150 In the index

Pentadeca arginate PDA

A newer trademarked peptide product marketed as related to BPC-157 for tissue repair and recovery. Like BPC-157, the supporting evidence is mostly from animal studies, without solid human trials proving it works or is safe.

Also known as PDA, BPC-157 arginate salt

Effects Heal

Routes Subcutaneous

Legal status Research chemical

WADA Not listed

Molecular Structure of C₆₂H₉₈N₁₆O₂₂

Drag to rotate · scroll to zoom

Chemistry

Formula: C62H98N16O22
Molar mass: 1419.5
CAS: 137525-51-0
PubChem CID: 9941957

Reported dosing

User-reported

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 250-500 mcg/day

Reported range 200-1000 mcg/day

Route Subcutaneous injection

Frequency Once or twice daily

Duration 4-8 week course (unregulated use)

Marketed as a more stable analog of BPC-157 (sometimes called PDA or BPC-157 arginate salt); no completed human clinical trials, sold only as a research chemical.

Where this comes from Animal studies only (parent compound); user-reported/research-chemical vendor literature

There is no approved human dosing for this compound. The figures above are what users and vendors report, not what has been established as safe or effective. Treat them as a record of what is done, not as guidance.